ALBO News and Press, Albireo Pharma Inc. From 08/16/22

Shares of small-cap liver disease treatments maker Albireo Pharma ( NASDAQ: ALBO ) fell 26.1% to $18.42 in Tuesday early trading, despite the company reporting a jump in quarterly revenue due to sales of liver disease-induced itchy skin drug Bylvay. The company also cut ...

Save Foods ( SVFD ) -35% on pricing of $4.8M stock offering . Albireo Pharma ( ALBO ) -23% on Q2 earnings release . Tremor International ( TRMR ) -17% on Q2 earnings release . GAN ( GAN ) -17% on Q2 earnings release . Hel...

Albireo Pharma press release ( NASDAQ: ALBO ): Q2 GAAP EPS of -$2.04. Revenue of $8.2M (+237.4% Y/Y). Bylvay(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 million For further details see: Albireo Pharma GAAP EPS of -$2.04, revenue ...

Bylvay ® (odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 million Agreed Bylvay reimbursement contract in Italy and Belgium with launches planned for the fall Global Phase 3 ASSERT study in Alagille syndrome on track for top...

– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children’s Hospital, bring significant global drug development, financial and commercial operations expertise to Albireo ...

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the 2022 Wedbush PacGrow Healthcare Conference August 9-10, 2022. R...

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 15, 2022, to provide a bu...

Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not yet appreciate the full potential of Bylvay, which presents a good entry opportunity for investors. Bylvay - a potential product as...

First successful global gold standard pediatric Phase 3 trial ever conducted in cholestatic liver disease PEDFIC 1 & 2 studies were foundational for the approval of Bylvay in the U.S. and Europe Study shows Bylvay provided statistically significant improvements in pr...

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biotech Focus Conference July 12-13, 2022. Ron Cooper, President and Chief Executive Officer,...